Difference between revisions of "Ramucirumab (Cyramza)"
m (updated content) |
m |
||
| Line 13: | Line 13: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *4/21/2014: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm394260.htm FDA approved] "for the treatment of patients with advanced or metastatic, gastric or gastroesophageal junction (GEJ) adenocarcinoma with disease progression on or after prior treatment with fluoropyrimidine- or platinum-containing chemotherapy." |
==Also known as== | ==Also known as== | ||
Revision as of 23:57, 23 April 2014
General information
Class/mechanism: Recombinant human IgG1 monoclonal antibody, VEGFR2 (vascular endothelial growth factor receptor 2) antagonist. Ramucirumab binds VEGFR2 and blocks VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D, which inhibits angiogenesis.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Brief patient counseling information can be found on page 9 of the package insert[1]
History of changes in FDA indication
- 4/21/2014: FDA approved "for the treatment of patients with advanced or metastatic, gastric or gastroesophageal junction (GEJ) adenocarcinoma with disease progression on or after prior treatment with fluoropyrimidine- or platinum-containing chemotherapy."
Also known as
IMC-1121B.